CD8⁺ T cells specific for the myeloid tumor epitope PR1 are retained after allodepletion after stimulation with mismatched LCLs but not CML PBMCs. (A) FACS analysis following staining with HLA-A2–PR1 tetramer of unmanipulated PBMCs (top row) or allodepleted PBMCs (bottom row) from a patient with CML. In each case isotype controls are shown on the left and tetramer-stained cells on the right. Allodepletion was performed after stimulation with allogeneic HLA-A2–positive PBMCs from a mismatched donor with CML. (B) FACS analysis following staining with HLA-A2–PR1 tetramer of unmanipulated PBMCs or allodepleted T cells from 2 HLA-A2–positive patients with CML. Allodepletion was performed after stimulation with either HLA-A2–positive or –negative LCLs. The percentages of tetramer-positive cells as a proportion of CD8⁺ cells (isotype subtracted) are shown.